Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research and Treatment
Erschienen in: Breast Cancer Research and Treatment 2/2008

01.01.2008 | Review

Insulin-like growth factor binding proteins and breast cancer

verfasst von: Ashok Subramanian, Anup Sharma, Kefah Mokbel

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Excerpt

The insulin-like growth factor (IGF) axis plays a key role in the growth, differentiation and proliferation of mammalian cells and although vital in many organ systems, has been shown to play a particular role in the normal development of the human mammary gland and has also been heavily implicated in mammary carcinogenesis [1, 2]. …
Literatur
1.
Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA et al (2006) Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. 1. Endocrinology 147(7):3484–3500PubMed
2.
Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocr Relat Cancer 8(3):197–209PubMed
3.
Marshman E, Streuli CH (2002) Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 4(6):231–239PubMed
4.
Clemmons DR, Cascieri MA, Camacho-Hubner C, McCusker RH, Bayne ML (1990) Discrete alterations of the insulin-like growth factor I molecule which alter its affinity for insulin-like growth factor-binding proteins result in changes in bioactivity. J Biol Chem 265(21):12210–12216PubMed
5.
Gershtein ES, Shatskaya VA, Ermilova VD, Kushlinsky NE, Krasil’nikov MA (1999) Phosphatidylinositol 3-kinase expression in human breast cancer. Clin Chim Acta 287(1–2):59–67PubMed
6.
Ram TG, Dilts CA, Dziubinski ML, Pierce LJ, Ethier SP (1996) Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Mol Carcinog 15(3):227–238PubMed
7.
Zhou X, Tan M, Stone HV, Klos KS, Lan KH, Yang Y et al (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10(20):6779–6788PubMed
8.
deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10(23):8059–8067PubMed
9.
Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M et al (2001) The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 28(5, suppl. 16):125–141PubMed
10.
Mills GB, Lu Y, Kohn EC (2001) Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 98(18):10031–10033PubMed
11.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943–1947PubMed
12.
Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL et al (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155(4):1253–1260PubMed
13.
Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO (2004) The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204(1):93–100PubMed
14.
Janes PW, Daly RJ, deFazio A, Sutherland RL (1994) Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9(12):3601–3608PubMed
15.
Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama KI, Endoh H et al (2000) Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells 5(8):593–601PubMed
16.
Sivaraman VS, Wang H, Nuovo GJ, Malbon CC (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99(7):1478–1483PubMed
17.
Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R et al (2004) Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100(3):499–506PubMed
18.
Zhang CC, Shapiro DJ (2000) Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. 2. J Biol Chem 275(1):479–486PubMed
19.
Kim MS, Lee EJ, Kim HR, Moon A (2003) p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells 46. Cancer Res 63(17):5454–5461PubMed
20.
Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI (2000) Biological and clinical associations of c-jun activation in human breast cancer. 1. Int J Cancer 89(2):177–186PubMed
21.
Vuori K, Ruoslahti E (1994) Association of insulin receptor substrate-1 with integrins. Science 266(5190):1576–1578PubMed
22.
Woodward TL, Xie J, Fendrick JL, Haslam SZ (2000) Proliferation of mouse mammary epithelial cells in vitro: interactions among epidermal growth factor, insulin-like growth factor I, ovarian hormones, and extracellular matrix proteins. 1. Endocrinology 141(10):3578–3586PubMed
23.
Hovey RC, Mackenzie DD, McFadden TB (1998) The proliferation of mouse mammary epithelial cells in response to specific mitogens is modulated by the mammary fat pad in vitro. In Vitro Cell Dev Biol Anim 34(5):385–392PubMed
24.
Deeks S, Richards J, Nandi S (1988) Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor. 1. Exp Cell Res 174(2):448–460PubMed
25.
Shamay A, Cohen N, Niwa M, Gertler A (1988) Effect of insulin-like growth factor I on deoxyribonucleic acid synthesis and galactopoiesis in bovine undifferentiated and lactating mammary tissue in vitro. Endocrinology 123(2):804–809PubMed
26.
Ruan W, Kleinberg DL (1999) Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 140(11):5075–5081PubMed
27.
Farrelly N, Lee YJ, Oliver J, Dive C, Streuli CH (1999) Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol 144(6):1337–1348PubMed
28.
Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM (1996) Targeted expression of des(1–3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 137(1):321–330PubMed
29.
Moorehead RA, Fata JE, Johnson MB, Khokha R (2001) Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice. Cell Death Differ 8(1):16–29PubMed
30.
Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr, Hennighausen L, LeRoith D (1996) Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 97(10):2225–2232PubMed
31.
Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ (2001) Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21(6):2203–2212PubMed
32.
Schwertfeger KL, Richert MM, Anderson SM (2001) Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol 15(6):867–881PubMed
33.
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer 98. Lancet 351(9113):1393–1396PubMed
34.
Vadgama JV, Wu Y, Datta G, Khan H, Chillar R (1999) Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57(4):330–340PubMed
35.
Renehan AG, Zwahlen M, Minder C, O’dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353PubMed
36.
Renehan AG, Harvie M, Howell A (2006) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. 1. Endocr Relat Cancer 13(2):273–278PubMed
37.
Paik S (1992) Expression of IGF-I and IGF-II mRNA in breast tissue. 8. Breast Cancer Res Treat 22(1):31–38PubMed
38.
Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ et al (1989) Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. 2. Mol Endocrinol 3(3):509–517PubMedCrossRef
39.
Toropainen EM, Lipponen PK, Syrjanen KJ (1995) Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis. 1. Anticancer Res 15(6B):2669–2674PubMed
40.
Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. 1. Endocr Rev 20(6):761–787PubMed
41.
LeRoith D, Baserga R, Helman L, Roberts CT Jr (1995) Insulin-like growth factors and cancer. Ann Intern Med 122(1):54–59PubMed
42.
Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK (2005) Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 41(11):1515–1527PubMed
43.
Kostecka Y, Blahovec J (1999) Insulin-like growth factor binding proteins and their functions (minireview). 2. Endocr Regul 33(2):90–94PubMed
44.
Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y et al (2004) Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. 2. Cancer Res 64(2):665–671PubMed
45.
Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. 1. Endocr Rev 23(6):824–854PubMed
46.
Schedlich LJ, Young TF, Firth SM, Baxter RC (1998) Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. 1. J Biol Chem 273(29):18347–18352PubMed
47.
Reinecke M, Collet C (1998) The phylogeny of the insulin-like growth factors. 1. Int Rev Cytol 183:1–94PubMedCrossRef
48.
Forbes BE, Turner D, Hodge SJ, McNeil KA, Forsberg G, Wallace JC (1998) Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain 16. J Biol Chem 273(8):4647–4652PubMed
49.
Neumann GM, Marinaro JA, Bach LA (1998) Identification of O-glycosylation sites and partial characterization of carbohydrate structure and disulfide linkages of human insulin-like growth factor binding protein 6. 2. Biochemistry 37(18):6572–6585PubMed
50.
Coverley JA, Baxter RC (1997) Phosphorylation of insulin-like growth factor binding proteins. 2. Mol Cell Endocrinol 128(1–2):1–5PubMed
51.
Coverley JA, Baxter RC (1995) Regulation of insulin-like growth factor (IGF) binding protein-3 phosphorylation by IGF-I. 3. Endocrinology 136(12):5778–5781PubMed
52.
Hashimoto R, Ono M, Fujiwara H, Higashihashi N, Yoshida M, Enjoh-Kimura T et al (1997) Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit. 3. J Biol Chem 272(44):27936–27942PubMed
53.
Lalou C, Lassarre C, Binoux M (1996) A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137(8):3206–3212PubMed
54.
Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y (1999) Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. 1. Endocrinology 140(3):1319–1328PubMed
55.
Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR (1993) Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. 3. Proc Natl Acad Sci USA 90(22):10553–10557PubMed
56.
Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. 1. Endocr Rev 18(6):801–831PubMed
57.
Radulescu RT (1994) Nuclear localization signal in insulin-like growth factor-binding protein type 3. 3. Trends Biochem Sci 19(7):278PubMed
58.
Wraight CJ, Liepe IJ, White PJ, Hibbs AR, Werther GA (1998) Intranuclear localization of insulin-like growth factor binding protein-3 (IGFBP-3) during cell division in human keratinocytes. 3. J Invest Dermatol 111(2):239–242PubMed
59.
Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, Keller GA (1997) Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. 4. Endocrinology 138(4):1763–1766PubMed
60.
Perks CM, Newcomb PV, Norman MR, Holly JM (1999) Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells. 6. J Mol Endocrinol 22(2):141–150PubMed
61.
Rajah R, Valentinis B, Cohen P (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. 1. J Biol Chem 272(18):12181–12188PubMed
62.
Andre F, Rigot V, Thimonier J, Montixi C, Parat F, Pommier G et al (1999) Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. 1. Int J Cancer 83(4):497–505PubMed
63.
Imai Y, Busby WH Jr, Smith CE, Clarke JB, Garmong AJ, Horwitz GD et al (1997) Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. 2. J Clin Invest 100(10):2596–2605PubMed
64.
Firth SM, Baxter RC (1999) Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. 4. J Endocrinol 160(3):379–387PubMed
65.
Jones JI, D’Ercole AJ, Camacho-Hubner C, Clemmons DR (1991) Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. 1. Proc Natl Acad Sci USA 88(17):7481–7485PubMed
66.
Nickerson T, Huynh H, Pollak M (1997) Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. 3. Biochem Biophys Res Commun 237(3):690–693PubMed
67.
Smits VA, Medema RH (2001) Checking out the G(2)/M transition. 3. Biochim Biophys Acta 1519(1–2):1–12PubMed
68.
Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM (2002) A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. 5. Biochem Biophys Res Commun 294(5):988–994PubMed
69.
Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM (1999) Differential IGF-independent effects of insulin-like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells. 1. J Cell Biochem 75(4):652–664PubMed
70.
Butt AJ, Firth SM, King MA, Baxter RC (2000) Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. 3. J Biol Chem 275(50):39174–39181PubMed
71.
Rajah R, Lee KW, Cohen P (2002) Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. 1. Cell Growth Differ 13(4):163–171PubMed
72.
Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D (1993) Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. 6. J Cell Biochem 52(2):196–205PubMed
73.
Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK (1990) Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. 2. Endocrinology 127(6):2679–2686PubMedCrossRef
74.
Pekonen F, Nyman T, Ilvesmaki V, Partanen S (1992) Insulin-like growth factor binding proteins in human breast cancer tissue. 1. Cancer Res 52(19):5204–5207PubMed
75.
Yee D, Favoni RE, Lippman ME, Powell DR (1991) Identification of insulin-like growth factor binding proteins in breast cancer cells. 2. Breast Cancer Res Treat 18(1):3–10PubMed
76.
Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS (1998) Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. 2. Epidemiology 9(5):570–573PubMed
77.
Bruning PF, Van DJ, Bonfrer JM, Van Noord PA, Korse CM, Linders TC et al (1995) Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. 4. Int J Cancer 62(3):266–270PubMed
78.
Baxter RC (2001) What is the significance of IGF-binding protein-3 proteolysis in the circulation? 2. J Clin Endocrinol Metab 86(10):5087–5088PubMed
79.
Oh Y (1998) IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 47(3):283–293PubMed
80.
Fowler CA, Perks CM, Newcomb PV, Savage PB, Farndon JR, Holly JM (2000) Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. 2. Int J Cancer 88(3):448–453PubMed
81.
Gill ZP, Perks CM, Newcomb PV, Holly JM (1997) Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. 4. J Biol Chem 272(41):25602–25607PubMed
82.
Huynh H, Yang X, Pollak M (1996) Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. 5. J Biol Chem 271(2):1016–1021PubMed
83.
Martin JL, Weenink SM, Baxter RC (2003) Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells: involvement of p44/42 and p38 mitogen-activated protein kinases. 1. J Biol Chem 278(5):2969–2976PubMed
84.
Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC (2004) Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. 1. J Clin Endocrinol Metab 89(4):1950–1956PubMed
85.
Conover CA (1991) Glycosylation of insulin-like growth factor binding protein-3 (IGFBP-3) is not required for potentiation of IGF-I action: evidence for processing of cell-bound IGFBP-3. 1. Endocrinology 129(6):3259–3268PubMed
86.
Conover CA (1992) Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism 11. Endocrinology 130(6):3191–3199PubMed
87.
De Mellow JS, Baxter RC (1988) Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. 1. Biochem Biophys Res Commun 156(1):199–204PubMed
88.
McCaig C, Perks CM, Holly JM (2002) Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. 2. J Cell Sci 115(pt 22):4293–4303PubMed
89.
Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL et al (2002) Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression 5. Eur J Cancer 38(18):2362–2370PubMed
90.
Jones JI, Gockerman A, Busby WH Jr, Camacho-Hubner C, Clemmons DR (1993) Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. 4. J Cell Biol 121(3):679–687PubMed
91.
Oh Y, Muller HL, Lamson G, Rosenfeld RG (1993) Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells: cell surface binding and growth inhibition. J Biol Chem 268(20):14964–14971PubMed
92.
Martin JL, Ballesteros M, Baxter RC (1992) Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. 1. Endocrinology 131(4):1703–1710PubMed
93.
Firth SM, Ganeshprasad U, Baxter RC (1998) Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3. 2. J Biol Chem 273(5):2631–2638PubMed
94.
Leal SM, Liu Q, Huang SS, Huang JS (1997) The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. 5. J Biol Chem 272(33):20572–20576PubMed
95.
Fanayan S, Firth SM, Baxter RC (2002) Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells: relationship to transforming growth factor-beta 1 signaling. 1. J Biol Chem 277(9):7255–7261PubMed
96.
McCaig C, Fowler CA, Laurence NJ, Lai T, Savage PB, Holly JM et al (2002) Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-beta) in normal vs cancerous breast epithelial cells. Br J Cancer 86(12):1963–1969PubMed
97.
Butt AJ, Fraley KA, Firth SM, Baxter RC (2002) IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. 1. Endocrinology 143(7):2693–2699PubMed
98.
Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D (1996) Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. 2. J Natl Cancer Inst 88(9):601–606PubMed
99.
Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV et al (1997) Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. 1. Clin Cancer Res 3(1):103–109PubMed
100.
Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kurosumi M et al (2004) Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. 3. Cancer Sci 95(6):496–502PubMed
101.
McCarthy K, Laban CA, Bustin SA, Ogunkolade BW, Carpenter R, Jenkins PJ (2003) Expression of insulin-like growth factor binding protein-3 (IGFBP-3) is down regulated in breast cancer compared to normal breast tissue. Endocrine Abstracts 2002:4
102.
Hao X, Sun B, Hu L, Lahdesmaki H, Dunmire V, Feng Y et al (2004) Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100(6):1110–1122PubMed
103.
Vestey SB, Perks CM, Sen C, Calder CJ, Holly JM, Winters ZE (2005) Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome. 2. Breast Cancer Res 7(1):R119–R129PubMed
104.
Kato MV (2000) A secreted tumor-suppressor, mac25, with activin-binding activity. Mol Med 6(2):126–135PubMed
105.
Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK (2003) Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. 1. Cancer Res 63(13):3783–3790PubMed
106.
St CB, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E et al (2000) Genes expressed in human tumor endothelium. 3. Science 289(5482):1197–1202
107.
Ahmed S, Yamamoto K, Sato Y, Ogawa T, Herrmann A, Higashi S et al (2003) Proteolytic processing of IGFBP-related protein-1 (TAF/angiomodulin/mac25) modulates its biological activity. 9. Biochem Biophys Res Commun 310(2):612–618PubMed
108.
Kanemitsu N, Kato MV, Miki T, Komatsu S, Okazaki Y, Hayashizaki Y et al (2000) Characterization of the promoter of the murine mac25 gene. Biochem Biophys Res Commun 279(1):251–257PubMed
109.
Komatsu S, Okazaki Y, Tateno M, Kawai J, Konno H, Kusakabe M et al (2000) Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). 8. Biochem Biophys Res Commun 267(1):109–117PubMed
110.
Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M et al (1998) Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. 9. Oncogene 16(19):2459–2467PubMed
111.
Landberg G, Ostlund H, Nielsen NH, Roos G, Emdin S, Burger AM et al (2001) Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. 7. Oncogene 20(27):3497–3505PubMed
112.
Seth A, Kitching R, Landberg G, Xu J, Zubovits J, Burger AM (2003) Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. 9. Anticancer Res 23(3A):2043–2051PubMed
113.
Swisshelm K, Ryan K, Tsuchiya K, Sager R (1995) Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. 1. Proc Natl Acad Sci USA 92(10):4472–4476PubMed
114.
Firth SM, Fanayan S, Benn D, Baxter RC (1998) Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. 3. Biochem Biophys Res Commun 246(2):325–329PubMed
115.
Wilson HM, Birnbaum RS, Poot M, Quinn LS, Swisshelm K (2002) Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. 1. Cell Growth Differ 13(5):205–213PubMed
Metadaten
Titel
Insulin-like growth factor binding proteins and breast cancer
verfasst von
Ashok Subramanian
Anup Sharma
Kefah Mokbel
Publikationsdatum
01.01.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9549-0

Weitere Artikel der Ausgabe 2/2008

Breast Cancer Research and Treatment 2/2008 Zur Ausgabe

Epidemiology

ATM allelic variants associated to hereditary breast cancer in 94 Chilean women: susceptibility or ethnic influences?

Preclinical Study

Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells

Preclinical Study

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases

Preclinical Study

Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome

Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary

A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk

Clinical Trial

Impact of chemotherapy beyond the first line in patients with metastatic breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise